Andrew Tustian, EngD

Executive Director at Regeneron

Speaker

Andrew leads the viral vector process development group at Regeneron Pharmaceuticals, focused on developing bioprocesses for Adeno-associated virus (AAV) based viral vectors to cure diseases such as Hemophilia B, congenital hearing loss, and Pompe disease. In April 2026 the first AAV therapy for hearing loss, Otarmeni™, was FDA-approved. Andrew also leads the fermentation development group at Regeneron, currently focused on plasmid production and design. Andrew has worked at Regeneron since 2009. Prior to moving to gene therapy Andrew co-led the purification development group for protein therapeutics, working on Fc-fusion, monoclonal antibody, and bispecific processes. He has worked on the process development for the multiple FDA-approved drugs including Dupixent®, Libtayo®, Inmazeb™, Kevzara®, Evkeeza™, Eylea HD™, and Praluent®, and helped develop the bispecific antibody platform at Regeneron. Andrew received his doctorate in biochemical engineering from University College London and his undergraduate masters in biochemistry from the University of Oxford.